Imbria Pharmaceuticals

Cardiac mitotropes (fatty-acid-oxidation modulators)

Privately held: no public share price · United States

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
2Diseases
Quick filter:
Showing 1 of 1 assets
Target & Modality
Ninerafaxstat(IMB-101)
Phase 2
Cardiac fatty-acid oxidationSmall molecule
Heart FailureHypertrophic Cardiomyopathy

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
Ninerafaxstat · IMB-101Phase 2Non-obstructive Hypertrophic Cardiomyopathy
Est. primary completion 2026-12 · NCT07023614 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

No financial reports recorded.